Published: May 12, 2021
ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL
LAUSANNE, Switzerland (BUSINESS WIRE) ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA™ in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in
The Lancet Oncology.
Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCLLAUSANNE, Switzerland (BUSINES.
ADC Therapeutics SA: ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology
ZYNLONTA demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in
Prostate cancer education is heading into Black barbershops through Case Western Reserve University program
Posted May 11, 2021
“Prostate cancer is big in our community,” says Urban Kutz Barbershops owner Waverly Willis, a member of the Case Comprehensive Cancer Center Community Advisory Board. Willis is part of a CWRU program that aims to educate Black men about prostate cancer by making information available in barbershops.
Facebook Share
CLEVELAND, Ohio In the African American community, barbershops are spaces where men shoot the breeze, hang with friends and get a trim. Thanks to a new Case Western Reserve University program, it’s where they’ll be able to learn about prostate cancer by year’s end.
The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
The CD19-targeted antibody drug conjugate (ADC) was granted accelerated approval by the US regulator based on overall response rate.
The approval also covers patients with DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
“This is the first ever approval of a PBD based ADC,” noted Chris Martin, CEO, ADC Therapeutics, on a conference call about the regulatory development and commercial launch.
The Lausanne, Switzerland based biotech is now entering